iShares Biotechnology ETF
$206.16−4.65 (−2.21%)
- Expense ratio
- 0.44%
- Fund size
- $10.5B
- 1Y return
- +47.3%
- Yield · Last 12 months
- 0.16%
- Holdings
- 244
- Volume · 30D
- 1.6M sh
- NAV per share
- $207.21
- 52W range
The ETF.net IBB Grade
Score 74 of 100 sits in the A band. Bands: A ≥ 70, B ≥ 55, C ≥ 40, D ≥ 25, F < 25; the scale skips E.
Cost
What you pay to own it — the expense ratio plus trading frictions, ranked within its category.BScore 69Category rankMission
How faithfully it does the job it claims — tracking its mandate or index with minimal slippage.AScore 83Category rankRisk
How violently it can move — volatility, drawdown depth, and downside capture versus its category.BScore 59Category rankTradability
How cheaply and easily you can get in and out — liquidity, spread, and premium/discount stability.AScore 96Category rankHoldings
What it actually owns — the quality, breadth, and concentration of the underlying portfolio.CScore 50Category rankDurability
Whether it will still be here — the fund’s assets, age, flows, and issuer staying power.AScore 89Category rank
Our read on IBB
ABiotech's original index fund. Since 2001 IBB has packed the whole US biotech sector, roughly 250 names, into one line item for 0.44% a year, below what the typical biotech fund charges.
The Fund seeks to track an index composed of U.S.-listed equities focused on the biotechnology sector.
Why people hold it
- A 2001 launch makes it one of the sector's originals, and it has grown into a multi-billion-dollar fund that trades actively.
- Roughly 250 stocks, so the whole US biotech bench comes along instead of a few marquee drugmakers.
- 0.44% a year, set by the prospectus and below the median fee in its biotech peer group.
- Sticks closely to the job in its prospectus: US-listed biotech equities, nothing exotic bolted on. That lands it in the upper half of its peer group.ishares.com
Worth knowing
- Cheaper seats exist in the same aisle: IBBQ at 0.19%, BBP at 0.34%, XBI at 0.35%.
- One industry carries the whole fund. Trial readouts, FDA decisions and patent expiries drive it, with no other sector to cushion a rough patch.
- Distributions arrive quarterly, but biotech is a growth sector and payouts are a side effect, not the point.
IBB Holdings
- Stocks
- 244
- 48%
- GILD
Sectors
- Health Care100.0%
Geography
- United States86.01%
- Netherlands4.20%
- Switzerland2.44%
- Denmark2.40%
- United Kingdom1.92%
- Ireland0.65%
- Germany0.64%
- Canada0.62%
- 1.10%
IBB Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
IBB$14,729
Returns run to the Sep 22, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | IBB |
|---|---|
| Year to date | +25.0% |
| 1 month | −1.3% |
| 3 months | +19.1% |
| 1 year | +47.3% |
| 3 years | +20.2% |
| 5 years | +4.5% |
| 10 years | +8.0% |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | IBB |
|---|---|---|
| 2026 YTD | +25.0% | |
| 2025 | +28.0% | |
| 2024 | −2.4% | |
| 2023 | +3.8% | |
| 2022 | −13.7% | |
| 2021 | +1.0% | |
| 2020 | +26.0% |
IBB in the news
IBB Dividends
- 0.16%
- $0.34
- $0.01 per share
- Quarterly
Distribution history
| Ex-date | Pay date | Amount per share |
|---|---|---|
| Sep 15, 2026 | Sep 18, 2026 | $0.01 |
| Jun 15, 2026 | Jun 18, 2026 | $0.02 |
| Mar 17, 2026 | Mar 20, 2026 | $0.12 |
| Dec 16, 2025 | Dec 19, 2025 | $0.18 |
| Sep 16, 2025 | Sep 19, 2025 | $0.08 |
| Mar 18, 2025 | Mar 21, 2025 | $0.12 |
| Dec 17, 2024 | Dec 20, 2024 | $0.06 |
| Sep 25, 2024 | Sep 30, 2024 | $0.20 |
| Mar 21, 2024 | Mar 27, 2024 | $0.13 |
| Dec 20, 2023 | Dec 27, 2023 | $0.12 |
| Sep 26, 2023 | Oct 2, 2023 | $0.15 |
| Jun 7, 2023 | Jun 13, 2023 | $0.0062 |
IBB Risk
- 19.0%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.72
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −39.0%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.71
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
IBB Cost
0.44%
IBB0.44%
- The middle half of Biotech & Genomics funds
- Median 0.47%
4 of the 15 Biotech & Genomics funds charge less.